Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1646
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | Non-Final OA | Janssen Biotech, Inc. |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | Non-Final OA | Genentech, Inc. |
| 18416031 | Anti-Jagged1 Antibodies and Methods of Use | Non-Final OA | Genentech, Inc. |
| 17605798 | FUSION POLYPEPTIDE COMPRISING Fc REGION OF IMMUNOGLOBULIN AND GDF15 | Final Rejection | LG CHEM, LTD. |
| 17933049 | Chimeric Antigen Receptors Comprising Interleukin-9 Receptor Signaling Domain | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17507414 | METHODS OF TREATING CROHN'S DISEASE | Non-Final OA | ELI LILLY AND COMPANY |
| 18484631 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES | Non-Final OA | Merck Sharp & Dohme LLC |
| 17284284 | EXTRACELLULAR VESICLES FOR TARGETED THERAPIES AGAINST MYELOID-DERIVED SUPPRESSOR CELLS | Final Rejection | Ohio State Innovation Foundation |
| 17254392 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD37 AND CD19 | Final Rejection | The General Hospital Corporation |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | Non-Final OA | BioNTech SE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy